PhRMA sues Trump administration over GLOBE drug pricing model

· Health · United States

The pharmaceutical industry's main trade group, PhRMA, is suing the Trump administration over a newly finalized demonstration program called GLOBE that ties Medicare drug prices to those paid in peer countries. The group filed suit after the administration completed the pilot program last week, arguing that mandatory international reference pricing would undercut the US drug market. It is the latest legal clash between brand drugmakers and the government over efforts to curb prescription costs, coming just days after the Justice Department issued a directive signaling it will pursue violations of federal law governing pharmaceutical marketing and pricing. The outcome of the case will shape how far the administration can push reference pricing into Medicare.

Why it matters：If the courts uphold GLOBE, international reference pricing could become a permanent feature of US Medicare, pressuring drugmakers' revenue and reshaping global pricing negotiations.

Key points

  • PhRMA, the brand drug industry's main trade group, filed the lawsuit against the Trump administration over the GLOBE pilot.
  • GLOBE ties Medicare drug prices to those paid in peer countries, a form of international reference pricing.
  • The suit follows a new Justice Department directive targeting fraud that covers violations of federal pharmaceutical law.

Sources (original reporting)

More stories from this day